EPIDEMIOLOGICAL PROFILE OF PROSTATE CANCER: COMPARATIVE ANALYSIS BETWEEN DATA FROM THE FEDERAL DISTRICT AND GOIÁS
DOI:
https://doi.org/10.63330/armv1n8-031Keywords:
Prostate cancer, Epidemiology, Public health, Mortality, ScreeningAbstract
The high incidence and mortality rates of prostate cancer make it essential to study its epidemiological profile to support more effective public health policies. This study aimed to analyze and compare the epidemiological profile of prostate cancer in the Federal District and the state of Goiás, considering variables such as incidence, hospitalizations, and mortality. This is a quantitative, descriptive, and retrospective study based on secondary data obtained from the InfoSaúdeDF platform, covering the period from 2019 to 2025. The results showed that the Federal District recorded 513 hospitalizations due to prostate cancer, while Goiás registered 60 in the same period. The highest concentration of cases occurred among men aged 60 to 69 years, and deaths were more frequent in individuals aged 80 years or older. Deaths were predominant among white individuals, followed by mixed-race individuals. The differences between the regions may be related to healthcare infrastructure, screening coverage, and data quality. It was concluded that the Federal District presents better indicators due to greater access to specialized services, whereas Goiás faces structural challenges and regional inequalities. The findings highlight the importance of early detection and equitable access to men's healthcare.
References
ATTARD, G. et al. Abiraterone acetate and prednisolone with or without enzalutamide for high‑risk non‑metastatic prostate cancer: a meta‑analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. The Lancet, v. 399, n. 10323, p. 447‑460, 2022. Disponível em: https://www.thelancet.com/article/S0140-6736(21)02437-5/fulltext. Acesso em: 21 out. 2025.
BOERRIGTER, E.; GROEN, L. N.; VAN ERP, N. P.; VERHAEGH, G. W.; SCHALKEN, J. A. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Review of Molecular Diagnostics, v. 20, n. 2, p. 219‑230, 2020. Disponível em: https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/115696-clinical-utility-of-emerging-biomarkers-in-prostate-cancer-liquid-biopsies.html Acesso em: 29 out. 2025.
BRASIL. Ministério da Saúde. Departamento de Informática do SUS – DATASUS: Informações de Saúde (TABNET). Brasília, 2024. Disponível em: https://datasus.saude.gov.br. Acesso em: 21 out. 2025.
BRASIL. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2022. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2023.pdf. Acesso em: 21 out. 2025. ( BRASIL, 2022).
BRASIL. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas do Câncer de Próstata. Brasília: Ministério da Saúde, 2022. Disponível em: https://www.gov.br/saude/pt-br/assuntos/pcdt.Acesso em: 21 out. 2025.
BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico, v. 53, n. 8, Saúde da população masculina no Brasil nos anos de 2010 a 2019: mortalidade por câncer de próstata. Brasília: Ministério da Saúde, 2022. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/edicoes/2022/boletim-epidemiologico-vol-53-no-08.pdf/@@download/file. Acesso em: 21 out. 2025.
EUROPEAN ASSOCIATION OF UROLOGY (EAU). EAU Guidelines – Prostate cancer: guidelines on prostate cancer. Disponível em: https://uroweb.org/guidelines/prostate-cancer. Acesso em: 21 out. 2025.
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC). Global Cancer Observatory – Cancer Today. Disponível em: https://gco.iarc.fr/today/.
MARCELINO AC, GOZZI B, CARDOSO-FILHO C, MACHADO H, ZEFERINO LC, VALE DB. Race disparities in mortality by breast cancer from 2000 to 2017 in São Paulo, Brazil: a population-based retrospective study. BMC Cancer 2021; 21(1):998. Disponível em: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08735-2. Acesso em: 29 out. 2025.
RAWLA, P. Epidemiology of prostate cancer. World Journal of Oncology, v. 10, n. 2, p. 63-89, 2019. Disponível em: https://www.wjon.org/index.php/wjon/article/view/1191/915.
REBELLLO, R. J. et al. Prostate cancer. Nature Reviews Disease Primers, v. 7, art. n. 9, 2021. Disponível em: https://www.nature.com/articles/s41572-020-00243-0Acesso em: 21 out. 2025.
SOUZA, R. C. et al. Rastreamento do câncer de próstata no Brasil: análise das desigualdades regionais. Revista de Saúde Pública, v. 56, p. 42, 2022. . Disponível em: DOI: https://doi.org/10.11606/s1518-8787.2022056003766. Acesso em: 29 out. 2025.
THOMPSON, J. E. et al. Diagnostic accuracy of multi parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet, v. 389, n. 10071, p. 815 822, 2017. Disponível em: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30121-6/fulltext.Acesso em: 21 out. 2025.
WANG G, ZHAO D, SPRING DJ, DEPINHO RA. Genetics and biology of prostate cancer. Genes Dev. 2018 Sep 1;32(17-18):1105-1140. doi: 10.1101/gad.315739.118. PMID: 30181359; PMCID: PMC6120714. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC6120714/. Acesso em: 29 out. 2025.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
